---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000011"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:18:18.430184+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q4 revenue $634M (+67% YoY); BRUKINSA sales $413M (+135%); operating loss narrows

## Summary
- Record total revenue $634M in Q4 (+67% YoY) and $2.5B full year (+74%); product revenue $630.5M (+86%).
- BRUKINSA global sales $413M in Q4 (+135% YoY) and $1.3B full year (+129%); U.S. revenue $313M in Q4.
- GAAP operating loss $383.8M in Q4, down 18% YoY; adjusted operating loss $267.2M, down 28%.
- FDA approved BRUKINSA label update for PFS superiority in CLL; EU approved for R/R follicular lymphoma.
- Advanced pipeline: sonrotoclax Phase 3 in CLL started; BTK CDAC BGB-16673 early data; TEVIMBRA CHMP positive opinion for NSCLC.

## SEC filing metadata
- accession: 0001651308-24-000011
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/0001651308-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/bgne-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000011
- JSON: https://secwatch.observer/filing/0001651308-24-000011.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000011.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported three months and year ended December 31, 2023 results: revenue $634.4 million and $2.5 billion.
  - Period: three months and year ended December 31, 2023
  - Revenue: $634.4 million and $2.5 billion
  - Result: reported results
  source text: EX-99.1 (EX-99.1) --- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates • Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods • Strengthened leadership in hematology with global BRUKINSA®
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/0001651308-24-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.